PV Orchestra

Main Menu

  • Home
  • Orchestra concert
  • Classical orchestra
  • Popular orchestra
  • Orchestra opera

PV Orchestra

Header Banner

PV Orchestra

  • Home
  • Orchestra concert
  • Classical orchestra
  • Popular orchestra
  • Orchestra opera
Popular orchestra
Home›Popular orchestra›The orchestra maintains the music for this method of public dissemination

The orchestra maintains the music for this method of public dissemination

By George M. Ortiz
July 7, 2022
0
0

Contrary to popular opinion, special purpose acquisition company (SPAC) mergers are not dead. The alternative IPO method is just to see tough times due to an unstable market.

Orchestra BioMed is the second company in recent weeks to jump on the SPAC bandwagon. Earlier this week, the New Hope, Pennsylvania-based company announced that it would be combining with Health Sciences Acquisitions Corporation 2.

The business combination is supported by a total of $20 million in forward purchase contracts and a guarantee agreement of up to $50 million.

Orchestra BioMed is in a strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy (CNT) as a potential integrated hypertension treatment for patients with pacemakers.

Back Beat CNT is a bioelectronic treatment compatible with standard pacemakers.

The recent randomized, double-blind, peer-reviewed pilot study MODERATO II showed that patients treated with the BackBeat CNT had marked reductions of 8.1 mmHg in ambulatory systolic blood pressure (SBP) over 24 hours and 12.3 mmHg office systolic blood pressure. (oSBP) compared to control patients at six months.

Orchestra BioMed said it plans to conduct a global pivotal trial to further evaluate the safety and efficacy of BackBeat CNT in lowering blood pressure in a similar target population of patients who were indicated for, and recently received a pacemaker implant.

The strategic collaboration with Medtronic will provide Orchestra BioMed with development, clinical and regulatory support for this planned multinational study. Upon regulatory approval, Medtronic will have worldwide rights to market BackBeat CNT-compatible pacing systems for this target population.

Orchestra BioMed will share in the revenue generated by Medtronic’s sales of BackBeat CNT compatible pacing systems.

Orchestra also received $40 million from Medtronic to bring its Series D to $110 million. The company also received a $20 million investment from RTW and investments from other existing Orchestra BioMed shareholders, including Perceptive Advisors, Terumo Corporation, SternAegis Ventures and others.

“These significant transactions further validate the potential of Orchestra BioMed’s flagship development programs and our new partnership-based business model. As a global leader in advanced pacemaker therapies, Medtronic is the ideal company to help us develop BackBeat CNT for the treatment of hypertension, which is remarkably common and poses a significant health risk to the pacemaker population. David Hochman, CEO and Co-Founder of Orchestra BioMed, said in a statement.

The company also announced a partnership with Terumo. The collaboration includes the execution of a global clinical program with the goal of obtaining regulatory approval for the commercial sale of Virtue SAB in multiple markets and indications. Terumo has made an upfront payment of $30 million to Orchestra BioMed and Terumo will potentially make additional clinical and regulatory milestone payments in the future.

Orchestra BioMed will significantly share Virtue SAB’s future commercial revenue through royalties and unit payments as the exclusive supplier to SirolimusEFR. Orchestra BioMed retains development and licensing rights to SirolimusEFR and other technologies used in Virtue SAB for clinical applications outside of coronary and peripheral vascular interventions.

“This new collaboration and our established strategic partnership with Terumo for the development and commercialization of the Virtue Sirolimus (SAB) angio-infusion balloon for the treatment of arterial disease illustrates our commitment to developing potential high-impact medical innovations with world leaders in medical technology,” Hochman said in a statement.

Return trend?

2021 has been a great year for medical technology companies that have gone public through SPACs. However, the good fortune of SPAC companies suddenly collapsed in 2022 as many abandoned this alternative method to a traditional IPO.

However, last month, Human Longevity broke the trend of medtech companies pulling out of SPACs. The San Diego, Calif.-based company has signed a non-binding letter of intent with Freedom Acquisition 1 Corporation for a business combination that is reportedly valued at $1 billion. The transaction is expected to close by 1Q23.

Human Longevity has developed an AI-based personalized health intelligence platform that combines genome sequencing, quantitative whole-body MRI and blood biomarkers, enabling early detection and mitigation risk assessments of critical diseases .

Categories

  • Classical orchestra
  • Orchestra concert
  • Orchestra opera
  • Popular orchestra

Recent Posts

  • ” Olivier ! » on stage at the Old Opera | Journal-news
  • Boston Symphony Orchestra conductor Gail Samuel explores how Tanglewood can be welcoming to everyone | Berkshire landscapes
  • Opera Festival Scotland announces 2022 Slate
  • Mostly Mozart Festival Orchestra, critic — the young conductor is a great talent
  • OrpheusPDX brings an old hand and a new vision to the Portland opera scene

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • November 2017
  • October 2017
  • July 2017
  • June 2017
  • May 2017
  • March 2017
  • February 2017
  • January 2017
  • November 2016
  • September 2016
  • February 2016
  • April 2015
  • January 2013
  • November 2012
  • Privacy Policy
  • Terms and Conditions